On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

The FDA granted the approval of Cabenuva and Vocabria to ViiV Healthcare. This was the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month.